Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2002; 87(02): 355-356
DOI: 10.1055/s-0037-1613006
DOI: 10.1055/s-0037-1613006
Letters to the Editor
Activated Recombinant Factor VII (rFVIIa) in Bleeding Management after Therapy with llb/llla-Inhibitor Tirofiban
Authors
Further Information
Publication History
Received
05 October 2001
Accepted
12 October 2001
Publication Date:
13 December 2017 (online)
-
References
- 1 Task Force Members. Bertrand ME, Simoons ML, Fox KAA. et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Eur Heart J 2000; 21: 1406-32.
- 2 PRISM-PLUS Study Investigators: Inhibition of the Platelet Glycoprotein Ilb/IIIa Receptor with Tirifiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. N Engl J Med. 1998; 338: 1488-97.
- 3 Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 629: 35.
- 4 Poon M-C. d’Oiron R and the International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrynolysis 2000; 11 (Suppl. 01) S55-S68.
- 5 Lusher J, Ingerslev J, Roberts Ft, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrynolysis 1998; 09 (Suppl. 01) 119-28.
- 6 Poon M-C, Demers C, Jobin F, Wu JWY. Recombinant Factor VIIa is effective for Bleeding and Surgery in Patients with Glanzmann Thrombasthenia. Blood 1999; 94: 3951-3.